🔎 Trials Near Me

Beranda › Kanker Payudara › Michigan › Detroit

Uji klinis Kanker Payudara di Detroit, MI

33 studi untuk Kanker Payudara mencari peserta di lokasi sekitar Detroit (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

The Vanguard Study: Testing a New Way to Screen for Cancer

Menerima pesertaSukarelawan sehat diterima
  • Henry Ford Hospital, Detroit
  • Henry Ford Medical Center - Detroit Northwest, Detroit
Usia 45 hingga 75 · Semua jenis kelamin · Diperbarui 5 Okt 2026 · NCT06995898

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Menerima pesertaStudi observasionalSukarelawan sehat diterima
  • Henry Ford Hospital, Detroit
  • Henry Ford Health Saint John Hospital, Detroit
Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05334069

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

Menerima pesertaFase 2
  • Henry Ford Hospital, Detroit
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT07102381

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Menerima peserta
  • Karmanos Cancer Center - Wayne State University, Detroit
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT07214532

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

Menerima pesertaFase 1
  • Barbara Ann Karmanos Cancer Institute, Detroit
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07114601

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

Menerima pesertaFase 1
  • Barbara Ann Karmanos Cancer Institute, Detroit
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07213791

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

Menerima pesertaFase 1/2
  • Karmanos Cancer Institute, Detroit
  • Brigitte Harris Cancer Pavilion BHCP, Detroit
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT06827236

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

Menerima pesertaFase 3
  • Karmanos Cancer Center, Detroit
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT07173751

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

Menerima pesertaFase 1
  • Karmanos Cancer Institiute, Detroit
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Sep 2026 · NCT06293898

A Phase 1/1b Study of IAM1363 in HER2 Cancers

Menerima pesertaFase 1
  • Henry Ford Cancer Institute, Detroit
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT06253871

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Menerima pesertaFase 1/2
  • Henry Ford Hospital, Detroit
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT05386108

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

Menerima pesertaFase 1/2
  • Wayne State University - Barbara Ann Karmanos Cancer Institute, Detroit
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT07287917

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Menerima pesertaFase 3
  • Wayne State University/Karmanos Cancer Institute, Detroit
  • Henry Ford Hospital, Detroit
  • Henry Ford Health Saint John Hospital, Detroit
Usia 18 hingga 60 · Wanita · Diperbarui 2 Sep 2026 · NCT05879926

A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer

Menerima peserta
  • Karmanos Cancer Institute, Detroit
Usia 22 ke atas · Semua jenis kelamin · Diperbarui 26 Agu 2026 · NCT07227831

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

Menerima pesertaFase 3
  • Wayne State University/Karmanos Cancer Institute, Detroit
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT06500481

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Menerima pesertaFase 2/3
  • Henry Ford Cancer- Detroit (Brigitte Harris Cancer Pavilion), Detroit
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Agu 2026 · NCT06926868

E-Mindfulness Approaches for Living After Breast Cancer

Menerima pesertaFase 3
  • Henry Ford Hospital, Detroit
Usia 18 hingga 50 · Semua jenis kelamin · Diperbarui 4 Agu 2026 · NCT06748222

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Menerima pesertaFase 1/2
  • Karmanos Cancer Institute, Detroit
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Agu 2026 · NCT05579366

Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts

Menerima pesertaSukarelawan sehat diterima
  • Henry Ford Health, Detroit
Usia 45 hingga 74 · Wanita · Diperbarui 31 Jul 2026 · NCT05625659

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

Menerima pesertaFase 1/2
  • Henry Ford Health Hospital, Detroit
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Jun 2026 · NCT05377996

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Menerima pesertaFase 1/2
  • Henry Ford Hospital, Detroit
Usia 18 ke atas · Wanita · Diperbarui 22 Jun 2026 · NCT05573126

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

Menerima pesertaFase 3
  • Henry Ford Health System, Detroit
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Mei 2026 · NCT06757634

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

Menerima pesertaFase 3
  • Wayne State University/Karmanos Cancer Institute, Detroit
  • Henry Ford Hospital, Detroit
  • Henry Ford Health Saint John Hospital, Detroit
Usia 50 hingga 70 · Semua jenis kelamin · Diperbarui 23 Apr 2026 · NCT04852887

A Study of the TheraBionic P1 Device in Breast Cancer

Menerima peserta
  • Karmanos Cancer Institute, Detroit
Usia 22 ke atas · Wanita · Diperbarui 21 Apr 2026 · NCT07218432

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

Menerima pesertaFase 1/2
  • Henry Ford Health System, Detroit
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Apr 2026 · NCT05785741

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Menerima pesertaFase 1/2
  • Karmanos Cancer Institute, Detroit
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Apr 2026 · NCT05735080

F-Tryptophan PET/CT in Human Cancers

Menerima pesertaFase 1
  • Karmanos Cancer Institute, Detroit
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Jan 2026 · NCT05556473

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

Menerima pesertaFase 3
  • Wayne State University/Karmanos Cancer Institute, Detroit
  • Henry Ford Hospital, Detroit
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Okt 2025 · NCT03418961

A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.

Menerima peserta
  • Karmanos Cancer Institute, Detroit
Usia 18 ke atas · Wanita · Diperbarui 18 Sep 2025 · NCT07095114

Uji klinis Kanker Payudara di kota lain

Studi lain di Detroit

Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.